bucindolol has been researched along with cgp 20712a in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carson, PE | 1 |
Bölck, B; Brixius, K; Bundkirchen, A; Mehlhorn, U; Schwinger, RH | 1 |
Baker, JG; Fretwell, L; Gardiner, SM; Hill, SJ; Kemp, P; March, J | 1 |
1 review(s) available for bucindolol and cgp 20712a
Article | Year |
---|---|
Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exercise; Heart Failure; Heart Rate; Hemodynamics; Humans; Imidazoles; Male; Metoprolol; Middle Aged; Propanolamines; Propranolol; Quality of Life; Stroke Volume; Time Factors; Vasodilator Agents; Xamoterol | 1999 |
2 other study(ies) available for bucindolol and cgp 20712a
Article | Year |
---|---|
Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Binding, Competitive; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Female; Guanylyl Imidodiphosphate; Heart Ventricles; Humans; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Isoproterenol; Male; Metoprolol; Middle Aged; Myocardial Contraction; Myocardium; Nebivolol; Propanolamines; Substrate Specificity; Sympathetic Nervous System; Sympathomimetics; Thermodynamics | 2001 |
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiovascular Agents; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Heart Rate; Humans; Imidazoles; Isoproterenol; Male; Phenoxyacetates; Phenoxypropanolamines; Propanolamines; Rats; Rats, Sprague-Dawley; Vascular Resistance; Xamoterol | 2011 |